Abstract:Objective: To investigate the clinical variables that might predict the outcome of developmental and epileptic encephalopathy (DEE) after vagus nerve stimulation (VNS) therapy and identify the risk factors for poor long-term outcome. Patients and methods: We retrospectively studied 32 consecutive children with drug-resistant DEE who had undergone VNS surgery from April 2019 to July 2021, which were not suitable for corpus callosotomy. In spite of combining valproic acid, levetiracetam, lamotrigine, topiramate, etc. (standard anti-seizure medicine available in China) it has not been possible to effectively reduce seizures in the population we investigate (Cannabidiol and brivaracetam were not available in China). A responder was defined as a frequency reduction decrease > 50%. Seizure freedom was defined as freedom from seizures for at least 6 months. Sex, electroencephalograph (EEG) group, neurodevelopment, time lag, gene mutation, magnetic resonance imaging (MRI), and epilepsy syndrome were analyzed with Fisher's exact test, The age at onset and age at VNS therapy were analyzed with Kruskal-Wallis test, statistical significance was defined as p < 0.05. And used the effect size to correction. Results: Among the 32 patients, the median age at VNS implantation was 4.7 years (range: 1–12 years). At the most recent follow-up, five children (15.6%) were seizure-free and 22 (68.8%) were responders. Univariate analysis demonstrated that the responders were significantly associated with mild development delay/intellectual disability ( p = 0.044; phi coefficient = 0.357) and a multifocal EEG pattern ( p = 0.022; phi coefficient = −0.405). Kaplan-Meier survival analyses demonstrated that a multifocal EEG pattern ( p = 0.049) and DEE without epileptic spasm (ES) ( p = 0.012) were statistically significant ( p = 0.030). Multivariate analysis demonstrated that DEE with ES had significant predictive value for poor long-term outcome ( p = 0.014, hazard ratio = 5.433, confidence interval = 1.402–21.058). Conclusions: Our study suggested that VNS was a generally effective adjunct treatment for DEE. Although the predictive factors for VNS efficacy remain unclear, it should be emphasized that patients with ES are not suitable candidates for epilepsy surgery. Further investigations are needed to validate the present results.

Is Thalamic DBS Synergistic With VNS in Drug Resistant Genetic Generalized Epilepsy?

Anterior Nucleus of the Thalamus Deep Brain Stimulation with Concomitant Vagus Nerve Stimulation for Drug-Resistant Epilepsy

Vagus nerve stimulation in children with drug-resistant epilepsy of monogenic etiology

Responsive neurostimulation of the thalamus improves seizure control in idiopathic generalised epilepsy: initial case series

Combination of or Transition between Deep Brain Stimulation and Responsive Neurostimulation for the Treatment of Drug-Resistant Epilepsy

Deep brain stimulation of thalamus for epilepsy

Electrical Stimulation in Epilepsy: Vagus Nerve and Brain Stimulation

Vagus nerve stimulation for treating developmental and epileptic encephalopathy in young children

Vagus nerve stimulation for drug-resistant epilepsy induced by tuberous sclerosis complex

The thalamus-precentral gyrus functional connectivity changes in epilepsy patients following vagal nerve stimulation

Neuromodulation for Refractory Epilepsy

Predictors of therapeutic response following thalamic neuromodulation for drug‐resistant pediatric epilepsy: A systematic review and individual patient data meta‐analysis

Vagus Nerve Stimulation for Pediatric Patients with Drug-Resistant Epilepsy Caused by Genetic Mutations: Two Cases

Add‐On Deep Brain Stimulation versus Continued Vagus Nerve Stimulation for Childhood Epilepsy (ADVANCE): A Partially Randomized Patient Preference Trial

Neurostimulation in generalized epilepsy: A systematic review and meta‐analysis

Efficacy of Vagal Nerve Stimulation for Pharmacoresistant Poststroke Epilepsy

Does response to vagus nerve stimulation for drug‐resistant epilepsy differ in patients with and without Lennox–Gastaut syndrome?

Identifying responders to vagus nerve stimulation based on microstructural features of thalamocortical tracts in drug-resistant epilepsy

Vagus nerve stimulation for pharmacoresistant epilepsy secondary to encephalomalacia: A single-center retrospective study

Comparison of efficiency between VNS and ANT-DBS therapy in drug-resistant epilepsy: A one year follow up study

Vagus Nerve Stimulation Therapy in Epilepsy: An Overview of Technical and Surgical Method, Patient Selection, and Treatment Outcomes